Interestingly, when comparing the proportion of tumor-reactive CD8+ TILs to CD4+ TILs, a significant difference in favor of CD8+ TIL responses was observed when pooling all cohorts together (p < 0.0001, n = 177, Figure 1C). The gene discussed is CD8A; the disease is neoplasm.